EMERYVILLE, Calif., Sept. 8,
2022 /PRNewswire/ -- Dynavax Technologies Corporation
(Nasdaq: DVAX), a commercial-stage biopharmaceutical company
developing and commercializing innovative vaccines, today announced
that Ryan Spencer, Chief Executive
Officer, will participate in a virtual fireside chat at the H.C.
Wainwright 24th Annual Global Investment Conference, being
held September 12-14, 2022.
The on demand presentation will be available, beginning
Monday, September 12, 2022 at
7:00 a.m. E.T. and may be accessed
through the "Events & Presentations" page on the "Investors"
section of the Company's website at
https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company
developing and commercializing innovative vaccines to help protect
the world against infectious diseases. The Company has two
commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine
(Recombinant), Adjuvanted], which is approved in the U.S. and the
European Union for the prevention of infection caused by all known
subtypes of hepatitis B virus in adults 18 years of age and older,
and CpG 1018® adjuvant, currently used in multiple adjuvanted
COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a
premier vaccine adjuvant through global research collaborations and
partnerships. Current collaborations are focused on adjuvanted
vaccines for COVID-19, seasonal influenza, universal influenza,
plague, shingles and Tdap. For more information about our marketed
products and development pipeline, visit www.dynavax.com and follow
Dynavax on LinkedIn.
Contacts:
Nicole
Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301620814.html
SOURCE Dynavax Technologies